Thomas L. Long

Corporate Officer/Principal bei PLX PHARMA WINDDOWN CORP.

Health Technology

Profil

Thomas L.
Long is currently the VP-Manufacturing & Technical Operations at PLx Pharma, Inc. He previously worked as the SVP & General Manager-Manufacturing Operations at Adams Respiratory Therapeutics, Inc.

Aktive Positionen von Thomas L. Long

Unternehmen	Position	Beginn
PLX PHARMA WINDDOWN CORP.	Corporate Officer/Principal	19.09.2017

Alle aktiven Positionen von Thomas L. Long

Ehemalige bekannte Positionen von Thomas L. Long

Unternehmen	Position	Ende
Adams Respiratory Therapeutics, Inc. Adams Respiratory Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adams Respiratory Therapeutics, Inc. manufactures over-the-counter remedies for respiratory ailments. The company's products include Mucinex, Mucinex DM, Maximum Strength Mucinex, Mucinex DM, Mucinex D, and the Delsym. It is a subsidiary of Reckitt Benckiser Corp. Adams Respiratory Therapeutics is headquartered in Chester, NJ	Corporate Officer/Principal	-

Sehen Sie sich die Erfahrung von Thomas L. Long im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Thomas L. Long im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	2
Adams Respiratory Therapeutics, Inc. Adams Respiratory Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adams Respiratory Therapeutics, Inc. manufactures over-the-counter remedies for respiratory ailments. The company's products include Mucinex, Mucinex DM, Maximum Strength Mucinex, Mucinex DM, Mucinex D, and the Delsym. It is a subsidiary of Reckitt Benckiser Corp. Adams Respiratory Therapeutics is headquartered in Chester, NJ	Health Technology
PLx Pharma, Inc. PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE.	Health Technology